ThromboGenics/Alcon's Jetrea gets strongest AMNOG endorsement yet from German HTA
This article was originally published in Scrip
Executive Summary
ThromboGenics/Alcon's Jetrea (ocriplasmin) for vitreomacular traction has won the strongest endorsement yet from German health technology appraisal institute IQWiG for a drug passing through the tough AMNOG pricing and reimbursement system. The institute thinks it offers "major" and "considerable" benefits over standard of care, which bodes well for the price that the firm will eventually be able to command in Germany.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.